Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adjustment disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    80 result(s) found for: Adjustment disorder. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2008-003421-17 Sponsor Protocol Number: CL3-20098-051 Start Date*: 2009-02-18
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    11.0 10018075 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005674-47 Sponsor Protocol Number: CL3-20098-050 Start Date*: 2007-10-26
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ...
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    10.0 10018075 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SE (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003699-37 Sponsor Protocol Number: CL3-20098-089 Start Date*: 2013-01-17
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10018075 Generalised anxiety disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) PL (Completed) FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002577-23 Sponsor Protocol Number: CL2-20098-040 Start Date*: 2004-12-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose doub...
    Medical condition: Generalised Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10018075 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-001216-35 Sponsor Protocol Number: CONCERTAATT4086 Start Date*: 2015-04-24
    Sponsor Name:Johnson & Johnson Taiwan Ltd
    Full Title: From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002263-17 Sponsor Protocol Number: BRN-C-2017-01 Start Date*: 2017-11-02
    Sponsor Name:BOIRON
    Full Title: Efficacy and safety of Passiflora Compose in patients newly diagnosed with adjustment disorder with anxiety, as first-line treatment, compared to alprazolam
    Medical condition: Adjustment disorder with anxiety
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10002861 Anxiety disorders and symptoms HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013789-17 Sponsor Protocol Number: CL3-20098-071 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004008-19 Sponsor Protocol Number: CL3-20098-045 Start Date*: 2005-08-23
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    3. SERVIER Research and Development ICTR (For United Kingdom only)
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for 8 weeks in out-patients with severe Major Depressive Disorder. A randomised double-blind, parallel...
    Medical condition: Severe Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-010902-13 Sponsor Protocol Number: F1J-MC-HMGF(a) Start Date*: 2010-08-03
    Sponsor Name:LILLY S.A.
    Full Title: Duloxetina versus placebo en el tratamiento de pacientes de avanzada edad con trastorno de ansiedad generalizada Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anx...
    Medical condition: Trastorno de ansiedad generalizada Generalized anxiety disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    11 10018105 Trastorno de ansiedad generalizada LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004881-17 Sponsor Protocol Number: CL3-20098-047 Start Date*: 2006-05-01
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major d...
    Medical condition: Major depressive episode in the framework of bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10004939 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) ES (Completed) FI (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023576-10 Sponsor Protocol Number: CL3-20098-083 Start Date*: 2011-06-06
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day giv...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-004009-10 Sponsor Protocol Number: CL3-20098-046 Start Date*: 2005-06-29
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind inte...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001696-36 Sponsor Protocol Number: IL2REG Start Date*: 2019-10-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG)
    Medical condition: Depressive episode in course of mood disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10012402 Depressive episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001818-14 Sponsor Protocol Number: RELATE-TRD Start Date*: 2013-12-20
    Sponsor Name:University Medical Center Groningen
    Full Title: RELATE and PREDICT TRD A pharmacological and neuroimaging study investigating neurobiological effects of Selective Serotonin Reuptake Inhibitors and Norepinephrine Reuptake inhibitors on dopaminer...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003986-25 Sponsor Protocol Number: ADAMPA Start Date*: 2017-05-05
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Impact of self-measurement of blood pressure and self-adjustment of antihypertensive medication in the control of hypertension and adherence to treatment. A pragmatic, randomized, controlled clinic...
    Medical condition: Arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004460-63 Sponsor Protocol Number: EXPO Start Date*: 2019-07-01
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opi...
    Medical condition: Opiod addiction
    Disease: Version SOC Term Classification Code Term Level
    23.1 10037175 - Psychiatric disorders 10013658 Drug addiction LLT
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-003001-94 Sponsor Protocol Number: MSGLP Start Date*: 2019-11-06
    Sponsor Name:Lekárska fakulta UK Bratislava
    Full Title: Use of GLP-1 analogs in the treatment of multiple sclerosis
    Medical condition: Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurode...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004960-64 Sponsor Protocol Number: F1J-MC-HMDW(b) Start Date*: 2005-05-13
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
    Medical condition: Generalised Anxiety Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002626-22 Sponsor Protocol Number: F1J-MC-HMDV(a) Start Date*: 2005-01-24
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
    Medical condition: Generalized Anxiety Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003190-29 Sponsor Protocol Number: HMNC-101 Start Date*: 2012-01-30
    Sponsor Name:HolsboerMaschmeyer NeuroChemie (HMNC) GmbH
    Full Title: Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication according to the the ABCB1 Gene
    Medical condition: - Major Depression, single or recurrent, without psychotic features - Bipolar Disorders, currently depressed, without psychotic features
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    14.1 10037175 - Psychiatric disorders 10004940 Bipolar II disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:02:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA